NCT03352310View on ClinicalTrials.gov

Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

December 30, 2020

Conditions
Hypoxic-Ischemic EncephalopathyHypoxia NeonatalCerebral Ischemia of NewbornAnemia, Neonatal
Interventions
BIOLOGICAL

autologous umbilical cord blood (UCB)

autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth

PROCEDURE

standard care

standard care procedure to the newborn infants presence of HIE and/or anemia

Trial Locations (1)

Unknown

RECRUITING

The Chinese University of Hong Kong, Shatin

Sponsors
All Listed Sponsors
collaborator

Chinese University of Hong Kong

OTHER

collaborator

China Spinal Cord Injury Network

NETWORK

lead

Mononuclear Therapeutics Ltd.

INDUSTRY

NCT03352310 - Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia | Biotech Hunter | Biotech Hunter